Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment

Summary

Platelet multidrug resistance protein4 (MRP4)-overexpression has a role in reducing aspirin action. Aspirin in vivo treatment enhances platelet MRP4 expression and MRP4 mediated transport inhibition reduces platelet function and delays thrombus formation. The aim of our work was to verify whether MRP4 expression is enhanced in platelets obtained from patients under chronic aspirin treatment and whether it correlates with residual platelet reactivity. We evaluated changes on mRNA and protein-MRP4 expression and platelet aggregation in four populations: healthy volunteers (HV), aspirin-free control population (CTR), patients who started the treatment less than one month ago (ASA<1 month patients) and aspirinated patients who started the treatment more than two months ago (ASA>2 months patients). In platelets obtained from ASA>2 months patients, it was found a statistically significant MRP4 enhancement of both mRNA and protein expression compared to HV, CTR and ASA<1 month patients. Platelets obtained from ASA>2 months patients that present high levels of platelet MRP4, have higher serum TxB₂ levels and collagen-induced platelet aggregation compared to patient with low levels of MRP4 in platelets. In addition collagen induced platelet aggregation is higher in in vitro aspirinated platelets obtained from patients with high levels of MRP4 patients compared to those obtained from patients with low MRP4 levels. We can assert that, in patients under chronic aspirin treatment, platelets that present high MRP4 levels have an increase of residual platelet reactivity, which is due in part to incomplete COX-1 inhibition, and in part to COX-1–independent mechanism.

Keywords

Platelet - MRP4 - platelet aggregation - aspirin - gene expression

• References

• 1 Patrono C, Garcia Rodriguez LA, Landolfi R. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
• 2 Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther 2014; 141: 69-78.
• 3 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
• 4 Eikelboom JW, Hankey GJ, Thom J. et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
• 5 Frelinger 3rd AL, Li Y, Linden MD. et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterisation. Circulation 2009; 120: 2586-2596.
• 6 Pulcinelli FM, Riondino S, Celestini A. et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Hae-most 2005; 03: 2784-2789.
• 7 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
• 8 Breet NJ, van Werkum JW, Bouman HJ. et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011; 97: 983-990.
• 9 Wurtz M, Grove EL, Wulff LN. et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010; 03: 828-835.
• 10 Gori AM, Marcucci R, Paniccia R. et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008; 100: 1136-1145.
• 11 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
• 12 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
• 13 Sofi F, Marcucci R, Gori AM. et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis. Int J Cardiol 2008; 128: 166-171.
• 14 Mayer K, Bernlochner I, Braun S. et al. Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry. J Am Coll Cardiol 2014; 64: 863-871.
• 15 Angiolillo DJ, Cho JR. Aspirin treatment and outcomes in patients undergoing percutaneous coronary intervention: is there a role for pharmacodynamic testing?. J Am Coll Cardiol 2014; 64: 872-874.
• 16 Mattiello T, Guerriero R, Lotti LV. et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011; 58: 752-761.
• 17 Massimi I, Guerriero R, Lotti LV. et al. Aspirin influences megakaryocytic gene expression leading to upregulation of Multidrug Resistance Protein-4 in human platelets. Br J Clin Pharmacol 2014; 78: 1343-1353.
• 18 Temperilli F, Di Franco M, Massimi I. et al. Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets. Vascul Pharmacol 2016; 76: 11-17.
• 19 Gradilone A, Pulcinelli FM, Lotti LV. et al. Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets 2008; 08: 414-420.
• 20 Lien LM, Chen ZC, Chung CL. et al. Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo. Eur J Pharmacol 2014; 737: 159-167.
• 21 Decouture B, Dreano E, Belleville-Rolland T. et al. Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood 2015; 126: 1823-1830.
• 22 Cheepala SB, Pitre A, Fukuda Y. et al. The ABCC4 membrane transporter modulates platelet aggregation. Blood 2015; 126: 2307-2319.
• 23 Temperilli F, Rina A, Massimi I. et al. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment. Platelets 2015; 26: 783-787.
• 24 Pulcinelli FM, Gresele P, Bonuglia M. et al. Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. Biochem Pharmacol 1998; 56: 1481-1484.
• 25 Freedman JE, Larson MG, Tanriverdi K. et al. Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation 2010; 122: 119-129.
• 26 Lindemann SW, Yost CC, Denis MM. et al. Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs. Proc Natl Acad Sci USA 2004; 101: 7076-7081.
• 27 Born GVR. The aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
• 28 Bai J, Lai L, Yeo HC. et al. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol 2004; 36: 247-257.
• 29 Bassand JP, Hamm C. New European guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction--what are the new and key messages. Pol Arch Med Wewn 2007; 117: 391-393.
• 30 Borgognone A, Pulcinelli FM. Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport. Thromb Haemost 2012; 108: 955-962.
• 31 FitzGerald GA, Oates JA, Hawiger J. et al. Endogenous biosynthesis of prosta-cyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688.
• 32 Santilli F, Rocca B, De Cristofaro R. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin „resistance”. J Am Coll Cardiol 2009; 53: 667-677.
• 33 Pulcinelli FM, Pignatelli P, Celestini A. et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Car-diol 2004; 43: 979-984.
• 34 Voora D, Cyr D, Lucas J. et al. Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol 2013; 62: 1267-1276.
• 35 Floyd CN, Goodman T, Becker S. et al. Increased platelet expression of glyco-protein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. Br J Clin Pharmacol 2014; 78: 320-328.
• 36 Gori AM, Grifoni E, Valenti R. et al. High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. Eur J Intern Med 2016; 30: 49-54.
• 37 Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med 2015; 08: 43-61.